In a major advancement for neurodegenerative disease management, the European Medicines Agency (EMA) has granted conditional approval to Donanemab , an anti-amyloid monoclonal antibody developed by Eli Lilly, for patients with early symptomatic Alzheimer’s disease . This decision follows promising data from the TRAILBLAZER-ALZ 2 trial, which showed that Donanemab significantly slowed clinical decline in cognition and daily functioning when started early in the disease course. Donanemab targets amyloid-beta plaques , one of the key pathological hallmarks of Alzheimer’s.
By binding to deposited amyloid, the drug facilitates its clearance from the brain, aiming to modify the underlying disease process rather than just manage symptoms. This makes it the second disease-modifying therapy after Lecanemab to gain regulatory traction in major markets signaling a paradigm shift in how clinicians…
